> ⚠️ Research Use Only: GHRP-6 is an investigational research peptide not approved by the FDA or any other regulatory authority for human use, diagnosis, treatment, or prevention of any condition. All information on this page is intended solely for licensed researchers and scientific professionals working in laboratory settings. This content does not constitute medical advice, and GHRP-6 must not be used on humans or animals outside of an approved research context.
---
What Is GHRP-6?
GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide with the amino acid sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂ that stimulates growth hormone (GH) release through selective activation of the ghrelin receptor (GHS-R1a) on pituitary somatotrophs. With a molecular weight of approximately 873 Da, GHRP-6 was one of the earliest synthetic peptidyl GH secretagogues characterized in the research literature and remains an important reference compound for studying the somatotroph axis, GH pulsatility, and the broader pharmacology of the growth hormone secretagogue receptor system.
Among all synthetic GHRPs, GHRP-6 holds particular historical significance: it was the first compound to definitively establish that a second, non-GHRH receptor pathway could drive substantial pituitary GH release. Its discovery opened an entirely new research field and eventually led to the identification of ghrelin — the endogenous ligand for GHS-R1a — retroactively explaining the pronounced appetite stimulation that characterized GHRP-6 in early human trials. Today, GHRP-6 is studied not only for its potent GH-releasing properties but for a steadily expanding portfolio of cytoprotective, cardioprotective, neuroprotective, and anti-fibrotic activities that are partially independent of its GH-stimulating action.
---
> 📊 Research suppliers: Explore and compare GHRP-6 suppliers on the GHRP-6 peptide page.
Historical Development: The First Synthetic GHRP
Bowers' Enkephalin Analogs
The origin of GHRP-6 traces to the laboratory of American endocrinologist Cyril Bowers at Tulane University in the late 1970s. Bowers observed that chemical analogs of enkephalin amide — an endogenous opioid pentapeptide — displayed unexpected growth hormone-releasing activity when applied to rat pituitary cultures in vitro. This discovery was serendipitous: enkephalins were being studied for opioid receptor activity, not GH secretion.
Over subsequent years, Bowers and colleagues systematically modified the enkephalin backbone to enhance GH-releasing potency while reducing opioid activity. This medicinal chemistry program eventually produced GHRP-6, first described and characterized in the early 1980s, as the first compound in the series with the capacity for robust, dose-related GH release both in vitro and in vivo across multiple species. Critically, GHRP-6 shared no structural similarity with GHRH (growth hormone-releasing hormone), clearly demonstrating the existence of a separate receptor mechanism governing pituitary GH secretion.
Establishing the GHS-R1a Pathway
GHRP-6 became the primary pharmacological tool for characterizing what was initially called the "growth hormone secretagogue receptor" (GHS-R). Studies throughout the late 1980s and 1990s used GHRP-6 to map the receptor's distribution in the pituitary and hypothalamus, establish its signal transduction properties, and demonstrate its distinct pharmacology from the GHRH receptor. The seminal 1998 study by Pandya and colleagues (PubMed) showed that GHRP-6 requires endogenous hypothalamic GHRH for maximal GH stimulation, revealing the cooperative interplay between the GHRH and GHS-R1a pathways that is now a cornerstone of GH secretagogue pharmacology.
The receptor was eventually cloned in 1996 by Howard and colleagues, and in 1999 the endogenous ligand ghrelin was identified by Kojima and colleagues at the National Institute of Physiological Sciences in Japan. Ghrelin's identification immediately explained GHRP-6's prominent appetite-stimulating properties, since ghrelin is now recognized as a key orexigenic signal produced primarily in the stomach wall.
GHRP-6 as the Precursor to Later GHRPs
GHRP-6's pharmacological profile — potent but non-selective, with significant appetite and HPA axis activation — motivated the development of second-generation GHRPs with improved selectivity. GHRP-2, hexarelin, and ultimately ipamorelin were all synthesized in attempts to retain GHRP-6's GH-releasing potency while eliminating its cortisol, prolactin, and appetite effects. In this sense, GHRP-6 serves as the founding reference compound against which all subsequent GHRPs have been benchmarked, making it indispensable to the research history of this peptide class.
---
Molecular Structure and Chemical Properties
Primary Sequence and Non-Natural Residues
GHRP-6 is a hexapeptide with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂. Several structural features are critical to its pharmacological activity:
Histidine at position 1: The N-terminal histidine is important for receptor recognition and binding at GHS-R1a. Its imidazole side chain participates in key contacts within the receptor binding pocket.
D-Tryptophan at position 2: The D-isomer (rather than the natural L-isomer) of tryptophan at position 2 is essential for GH-releasing activity. Early structure-activity studies by Bowers demonstrated that substituting L-Trp at this position dramatically reduced potency. The D-amino acid confers both receptor specificity and improved metabolic stability by resisting aminopeptidase cleavage.
Tryptophan at position 4: The L-tryptophan at position 4 contributes to the hydrophobic pharmacophore required for receptor binding. The dual tryptophan residues at positions 2 and 4 form a characteristic motif shared with several other GHRPs, including GHRP-2 and hexarelin.
D-Phenylalanine at position 5: Another D-amino acid substitution that enhances resistance to enzymatic degradation and helps maintain the bioactive conformation necessary for GHS-R1a binding.
C-terminal Lysine-NH₂: The C-terminal lysine with an amide rather than free carboxylate termination is a common feature in synthetic GHRPs and contributes to receptor binding affinity and metabolic stability.
Physicochemical Properties
- •Molecular formula: C₄₆H₅₆N₁₂O₆
- •Molecular weight: 873.01 Da
- •CAS Number: 87616-84-0
- •Solubility: Soluble in water and aqueous buffers; typically reconstituted in bacteriostatic water for research use
- •Appearance: White to off-white lyophilized powder
- •Storage (lyophilized): -20°C, protected from moisture and light; stable for 24+ months
- •Storage (reconstituted): 2–8°C for up to 4 weeks; avoid repeated freeze-thaw cycles
- •pKa characteristics: Multiple ionizable groups (imidazole of His, ε-amino of Lys, α-amino terminus) render the molecule net positively charged at physiological pH
Receptor Binding Profile
Unlike the more selective second-generation GHRPs, GHRP-6 engages multiple receptor sites:
1. GHS-R1a (ghrelin receptor): Primary target mediating GH release, appetite stimulation, and hypothalamic effects. Binds with nanomolar affinity.
2. CD36 receptor: GHRP-6 binds the ectodomain of CD36, a scavenger receptor expressed on cardiomyocytes, endothelial cells, macrophages, and other cell types. CD36 binding is responsible for a significant portion of GHRP-6's cytoprotective, cardioprotective, and anti-fibrotic effects — activities that persist even in GHS-R1a knockout models.
This dual-receptor pharmacology distinguishes GHRP-6 from most other GHRPs and accounts for its unusually broad biological activity profile.
---
Mechanism of Action
GHS-R1a Signaling at the Pituitary
GHRP-6 binds with high affinity to GHS-R1a, a seven-transmembrane G protein-coupled receptor (GPCR) expressed at highest density on somatotroph cells of the anterior pituitary gland. Upon binding, GHRP-6 activates the receptor through the Gq/11 signaling pathway, initiating the following intracellular cascade:
1. PLC activation: Gq coupling activates phospholipase C (PLC), which hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP₂) into diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP₃).
2. Calcium mobilization: IP₃ triggers calcium release from the endoplasmic reticulum, while DAG activates protein kinase C (PKC). The resulting calcium transient is the primary trigger for exocytosis of GH-containing secretory granules.
3. PKC-mediated calcium influx: PKC activation additionally opens voltage-gated calcium channels in the plasma membrane, providing a sustained calcium influx that amplifies and prolongs the secretory response.
4. cAMP pathway co-activation: GHS-R1a also engages Gs coupling and adenylyl cyclase, increasing intracellular cAMP and activating protein kinase A (PKA), providing secondary signal amplification. Studies have confirmed that GHRP-6 stimulates phosphatidylinositol (PI) turnover in human pituitary somatotroph cells (PubMed, 1995).
This dual Gq/Gs signaling mechanism generates a more robust and sustained GH secretory response than activation of either pathway alone — explaining why GHRP-6 is one of the most potent synthetic GH secretagogues in the GHRP class.
Hypothalamic Actions: Somatostatin Suppression and GHRH Synergy
GHRP-6 exerts significant activity at the hypothalamic level that contributes to its GH-releasing efficacy:
Somatostatin inhibition: GHS-R1a is expressed on somatostatin-secreting neurons in the periventricular nucleus of the hypothalamus. GHRP-6 binding suppresses somatostatin (SRIF) release, reducing the inhibitory brake on pituitary somatotrophs. This disinhibition amplifies the GH response to both GHRP-6 itself and to concurrent GHRH stimulation.
GHRH potentiation: GHRP-6 enhances GHRH-stimulated GH release through complementary intracellular signaling. The Gq/calcium pathway activated by GHRP-6 synergizes with the Gs/cAMP pathway activated by GHRH, producing GH responses that substantially exceed the algebraic sum of each pathway's individual contribution. This synergy is the mechanistic basis for combining GHRP-6 with GHRH analogs such as CJC-1295 or Sermorelin in research protocols. Critically, the 1995 Popovic study demonstrated that GHRP-6 requires endogenous hypothalamic GHRH for maximal GH stimulation — exogenous GHRP-6 plus intact GHRH signaling yields significantly greater GH output than GHRP-6 alone in animals with GHRH receptor blockade.
CD36 Receptor Signaling: The Cytoprotective Arm
Separate from its GHS-R1a activity, GHRP-6 binds to the ectodomain of CD36 (cluster of differentiation 36), a multifunctional scavenger receptor involved in fatty acid uptake, lipid metabolism, oxidized LDL recognition, and apoptotic cell clearance. In cardiac myocytes and other cell types, CD36 engagement by GHRP-6 activates the PI3K/Akt prosurvival signaling cascade:
- •PI3K/Akt activation: Phosphorylation of Akt (protein kinase B) promotes cell survival by phosphorylating and inactivating pro-apoptotic proteins (BAD, caspase-9, FOXO transcription factors) while activating anti-apoptotic effectors (Bcl-2, Bcl-xL) and stimulating mTOR-dependent protein synthesis.
- •NF-κB modulation: GHRP-6/CD36 signaling modulates inflammatory transcription through NF-κB, reducing the production of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) in response to ischemic or chemical injury.
- •Anti-fibrotic gene regulation: GHRP-6 decreases transcription of TGF-β1 (transforming growth factor-β1) and CTGF (connective tissue growth factor) — the master regulators of fibroblast activation and extracellular matrix deposition — while inducing PPARγ (peroxisome proliferator-activated receptor gamma) and MMP-13, which promote matrix remodeling and inhibit pathological fibrosis.
This CD36-mediated activity constitutes a pharmacological action entirely distinct from GHRP-6's growth hormone axis effects and explains why cytoprotective studies of GHRP-6 have demonstrated effects even in conditions where GH signaling is minimal or absent.
---
GH Release Profiles and Pharmacokinetics
Potency and Dose-Response Characteristics
GHRP-6 is one of the most potent synthetic GHRPs in terms of peak GH output. Comparative studies in conscious swine established an ED₅₀ of approximately 3.9 ± 1.4 nmol/kg for GH release, with a maximal response (Emax) of approximately 74 ± 7 ng GH/mL plasma. For comparison, ipamorelin achieves similar Emax values (65 ± 0.2 ng GH/mL) at a lower ED₅₀ (2.3 ± 0.03 nmol/kg), reflecting subtly greater potency for ipamorelin at the GHS-R1a level, while GHRP-2 shows higher potency but lower maximum efficacy.
In human research subjects, GHRP-6 at doses of 1–2 mcg/kg administered intravenously or subcutaneously produces robust, dose-dependent GH release within 15–30 minutes. Important dose-response features include:
Saturation kinetics: There is a ceiling effect for GH release at approximately 100 mcg per subcutaneous injection in adult subjects. Doses above this threshold do not proportionally increase GH output but do increase co-secretion of cortisol, ACTH, and prolactin — the non-selective effects that distinguish GHRP-6 from more selective GHRPs.
GH pulse characteristics: GHRP-6 produces sharp, pulsatile GH spikes with peak GH concentrations typically reached 15–45 minutes post-injection, followed by return to baseline within 2–4 hours. This pulsatile pattern is more physiologically appropriate than continuous GH infusion and helps preserve GH receptor sensitivity.
Timing of injections: GH release in response to GHRP-6 is significantly blunted by elevated blood glucose and free fatty acids, which enhance somatostatin tone. Research protocols typically administer GHRP-6 in a fasted state to maximize the GH response.
Pharmacokinetics
GHRP-6's plasma pharmacokinetics following subcutaneous administration are characterized by:
- •Half-life: Approximately 15–60 minutes (shorter at lower doses; extended somewhat by the D-amino acid substitutions that resist proteolytic degradation)
- •Time to peak (T_max): 15–30 minutes post-subcutaneous injection
- •Bioavailability (subcutaneous vs. IV): Subcutaneous bioavailability is adequate for research use, though somewhat lower than intravenous delivery
- •Distribution: Primarily extracellular compartment; limited tissue accumulation
- •Metabolism: Proteolytic cleavage by circulating and tissue peptidases; renal clearance of metabolites
The peptide's relatively short half-life means that GH stimulation from any single injection is transient — a property that mirrors natural GH pulsatility and is considered preferable to sustained pharmacological GH elevation.
---
IGF-1 Elevation and Anabolic Signaling
Acute vs. Sustained IGF-1 Changes
Single acute doses of GHRP-6 produce significant GH spikes but have only modest effects on circulating IGF-1, since the liver requires sustained or repeated GH stimulation to substantially increase IGF-1 synthesis and secretion. Studies examining chronic GHRP-6 administration protocols (multiple injections daily over weeks) consistently demonstrate measurable IGF-1 elevation.
A clinical review examining growth hormone secretagogue therapy found that men with a mean baseline IGF-1 of approximately 159.5 ng/mL achieved a mean post-treatment IGF-1 of 239.0 ng/mL following thrice-daily GHRP/SERM protocols — representing approximately 50% elevation from baseline. The magnitude of IGF-1 elevation depends on:
- •Baseline IGF-1 and GH secretory capacity: Subjects with greater functional reserve respond more robustly
- •Injection frequency: Three daily injections consistently produce greater IGF-1 elevation than once-daily protocols
- •Administration timing: Evening injection timing leveraging the natural nocturnal GH surge appears to maximize integrated GH exposure
- •Concomitant GHRH analog use: Adding a GHRH analog (CJC-1295 or Sermorelin) to GHRP-6 produces substantially greater IGF-1 elevation than GHRP-6 alone, due to synergistic GH release
Research in aged rats by Cella and colleagues showed that chronic hexarelin and GHRP-6 administration stimulated GH secretion but produced only modest IGF-1 elevations compared with younger animals — consistent with the known age-related decline in hepatic IGF-1 responsiveness to GH, and relevant to aging research contexts where somatotropic axis restoration is being investigated.
IGF-1-Mediated Anabolic Effects
IGF-1 generated in response to GHRP-6-stimulated GH release acts on muscle, bone, and adipose tissue:
Muscle: IGF-1 activates the PI3K/Akt/mTOR pathway in skeletal muscle, promoting protein synthesis and satellite cell proliferation. Simultaneously, GH's direct lipolytic effects on adipose tissue support nitrogen preservation by reducing protein catabolism for fuel.
Bone: Both GH and IGF-1 stimulate osteoblast proliferation and differentiation. Chronic elevation in GH/IGF-1 tone from repeated GHRP-6 administration in animal models has been associated with increased bone mineral density and cortical thickness, consistent with the known importance of the GH axis in bone homeostasis.
Adipose tissue: GH exerts direct lipolytic effects on adipocytes independent of IGF-1, stimulating hormone-sensitive lipase activity and mobilizing stored triglycerides. Over time, repeated GH pulsing from GHRP-6 protocols in animal studies has been associated with shifts in body composition favoring reduced fat mass.
---
Appetite Stimulation: GHRP-6's Defining Off-Target Effect
The Ghrelin Connection
GHRP-6's appetite-stimulating properties were puzzling at the time of its discovery but were retroactively explained by the identification of ghrelin in 1999. Ghrelin, a 28-amino acid acylated peptide produced primarily by X/A-like cells of the gastric fundus, is the endogenous ligand for GHS-R1a. Its central functions include stimulating GH release from the pituitary, regulating energy homeostasis, and — crucially — acting as the primary circulating hunger signal.
GHRP-6's structural mimicry of ghrelin means it activates GHS-R1a not only on pituitary somatotrophs but also on orexigenic neuropeptide Y (NPY) and agouti-related protein (AgRP) neurons in the hypothalamic arcuate nucleus, on vagal afferents in the gut-brain axis, and in reward-processing regions including the ventral tegmental area. The result is a robust appetite signal that preclinical and clinical studies consistently describe as the most pronounced orexigenic effect among the synthetic GHRPs.
Quantifying the Appetite Effect
In comparative studies, GHRP-6 produces stronger appetite stimulation than GHRP-2, hexarelin, or ipamorelin at equivalent GH-releasing doses. Healthy volunteers given GHRP-6 in controlled research settings reported significant increases in hunger ratings within 30–60 minutes of injection, with caloric intake at ad libitum meals meaningfully increased compared to placebo. This orexigenic effect has implications for research protocol design:
- •Body composition studies: If caloric intake is not controlled, GHRP-6's appetite stimulation can confound outcomes related to fat mass changes, introducing a variable that obscures the specific effects of elevated GH/IGF-1
- •Metabolic research: Studies examining energy expenditure, substrate utilization, or insulin sensitivity must account for both the GH effect and the concurrent appetite signal
- •Comparison with ipamorelin: In research contexts where isolating the GH/IGF-1 axis is the primary goal, ipamorelin's absence of appetite stimulation provides a cleaner experimental signal
GHRP-6 administration in rats increases IGF-I mRNA and phosphorylated Akt levels in the hypothalamus, suggesting that GHRP-6 not only stimulates appetite acutely but may have longer-term trophic effects on hypothalamic neuropeptide systems (PubMed, 2005).
---
Cortisol, ACTH, and Prolactin: The Non-Selective Hormonal Profile
HPA Axis Activation
Unlike ipamorelin (which does not significantly elevate ACTH or cortisol at any studied dose), GHRP-6 robustly stimulates the hypothalamic-pituitary-adrenal (HPA) axis in a dose-dependent manner. A 1999 study by Frieboes and colleagues demonstrated that repeated intravenous boluses of GHRP-6 during sleep elevated serum GH, ACTH, and cortisol levels. This HPA activation occurs through GHS-R1a signaling in the hypothalamic paraventricular nucleus, increasing CRH (corticotropin-releasing hormone) secretion and consequently ACTH and cortisol.
The cortisol response to GHRP-6 has practical implications for research:
Catabolic confounding: Cortisol is catabolic in muscle and bone — directly opposing the anabolic GH/IGF-1 signal. In body composition research, concurrent cortisol elevation from GHRP-6 creates a competing hormonal signal that can attenuate or confound the anabolic outcomes of interest.
Metabolic effects: Cortisol promotes insulin resistance, gluconeogenesis, and visceral adiposity — all endpoints that overlap with GH research endpoints, making attribution of effects difficult.
Dose-threshold behavior: The GH response to GHRP-6 plateaus at approximately 100 mcg (subcutaneous), but cortisol and prolactin co-secretion continues to increase with higher doses. This means there is no dose at which GHRP-6 is both maximally effective for GH and minimally intrusive for cortisol — a fundamental selectivity limitation.
Prolactin Elevation
GHRP-6 also elevates prolactin modestly compared to baseline. While the prolactin response is typically smaller in magnitude than the cortisol response, elevated prolactin can confound research studies examining reproductive function, immune regulation, or metabolic parameters, since prolactin has diverse peripheral effects beyond lactation.
---
Cytoprotective Research: Beyond Growth Hormone
Cardioprotective Effects
Among the most significant research discoveries of the past two decades is the extent of GHRP-6's cardioprotective pharmacology. Studies using a porcine acute myocardial infarction model demonstrated that GHRP-6 administration reduced infarct mass by approximately 78% and preserved ventricular wall thickness by 50% compared to saline controls — a dramatic protective effect mediated primarily through CD36-dependent PI3K/Akt signaling rather than GH axis effects.
A landmark 2024 study published in Frontiers in Pharmacology (full text) demonstrated that GHRP-6 prevents doxorubicin-induced myocardial and extra-myocardial damage by activating prosurvival mechanisms. Doxorubicin (an anthracycline chemotherapy agent) produces dose-limiting cardiotoxicity through oxidative stress and cardiomyocyte apoptosis — and GHRP-6's PI3K/Akt activation substantially attenuated this damage in preclinical models.
The cardioprotective mechanisms demonstrated in the literature include:
- •Anti-apoptotic signaling: PI3K/Akt/Bcl-2 pathway activation reduces cardiomyocyte apoptosis during ischemia-reperfusion injury
- •Inotropic activity: GHRP-6 produces a positive inotropic effect mediated by elevation of intracellular calcium via PLC/DAG/PKC and voltage-gated calcium channels — potentially relevant in heart failure models
- •Anti-inflammatory reduction: Reduction of TNF-α and IL-6 production in cardiac tissue limits secondary inflammatory injury following ischemic events
- •Reduction of oxidative stress: Activation of antioxidant defenses (superoxide dismutase, catalase, glutathione peroxidase) protects cardiomyocyte membranes from lipid peroxidation
Neuroprotective Properties
GHRP-6's neuroprotective effects have been investigated in multiple preclinical ischemia models. Co-administration of epidermal growth factor (EGF) and GHRP-6 within 4 hours of ischemic insult in rodent stroke models significantly improved survival, reduced infarct volume, and improved neurological outcome scores. This neuroprotective combination has advanced to human trials.
A Phase I/II clinical trial published in Frontiers in Neurology in 2024 (Frontiers) enrolled patients aged 18–80 with acute ischemic stroke, randomly assigning them to groups receiving 3.5 mg or 5 mg GHRP-6 intravenously twice daily for 7 days (combined with EGF). The trial reported that EGF + GHRP-6 therapy was safe and showed functional benefits that support advancement to a Phase III study — a remarkable translational step for a peptide originally developed purely as a GH secretagogue.
The neuroprotective mechanisms proposed from preclinical data include:
- •Reduction of excitotoxicity: GHS-R1a activation in hippocampal neurons may modulate glutamate release and calcium-mediated excitotoxic cell death
- •Neurotrophic axis stimulation: GH and IGF-1 generated by GHRP-6 administration have established neuroprotective properties; IGF-1 receptors are expressed on neurons throughout the CNS and activation promotes survival, synaptic plasticity, and neurogenesis
- •Anti-apoptotic protection: CD36-mediated PI3K/Akt signaling protects neurons from apoptosis following ischemic or oxidative insult
Anti-Fibrotic Research
GHRP-6 has emerged as a potentially important anti-fibrotic agent, with research spanning liver fibrosis, cutaneous fibrosis, and kidney fibrosis models:
Liver fibrosis: In rats with carbon tetrachloride (CCl₄)-induced liver cirrhosis, GHRP-6 administration reduced fibrotic induration by more than 75%, decreased cords thickness, and reduced the number of cirrhotic nodules by up to 60%, while exerting a marked hepatoprotective effect on residual hepatocytes. These findings identify GHRP-6 as a potential therapeutic tool in fibrotic liver disease, an area of substantial unmet medical need.
Wound healing and scar prevention: A study published in Plastic Surgery International (2016) demonstrated that GHRP-6 applied to simple wound models in rats increased the rate of wound closure and decreased inflammatory infiltrate. More dramatically, in a model of hypertrophic scarring in rabbit ears, GHRP-6 prevented keloid formation in more than 90% of treated wounds — a striking result suggesting utility in preventing pathological scar formation.
A subsequent proteomics study published in 2021 (PMC) elucidated the molecular mechanism: GHRP-6 downregulates TGF-β1 and CTGF while upregulating PPARγ and MMP-13, creating an anti-fibrotic transcriptional program that suppresses myofibroblast activation and excessive extracellular matrix deposition. This mechanistic insight aligns with the proposed antagonistic relationship between PPARγ and TGF-β1 signaling in fibrosis.
Broader anti-fibrotic potential: Given that excessive TGF-β1 signaling drives fibrosis in virtually every organ system, researchers have proposed GHRP-6 as a candidate for fibrotic disorders beyond liver and skin — including pulmonary fibrosis, renal fibrosis, and cardiac fibrosis following myocardial infarction.
---
GHRP-6 vs. Other Growth Hormone Secretagogues
Understanding GHRP-6 in context requires comparing it systematically with the broader GHRP/secretagogue landscape.
GHRP-6 vs. GHRP-2
GHRP-2 (D-Ala-D-(β-2-Nal)-Ala-Trp-D-Phe-Lys-NH₂) is the closest structural analog to GHRP-6, with higher receptor binding affinity and greater potency for GH release. However, GHRP-2 produces even more pronounced cortisol and prolactin elevations than GHRP-6, with a more marked HPA axis stimulation. Researchers who prioritize raw GH-stimulating potency may favor GHRP-2; those seeking a moderate GH response with somewhat less non-selective stimulation may prefer GHRP-6.
GHRP-6 vs. Hexarelin
Hexarelin (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂) is the most potent of the hexapeptide GHRPs for acute GH release, but like GHRP-6 it substantially elevates cortisol and prolactin. Hexarelin also demonstrates significant tachyphylaxis (desensitization) with chronic use — a phenomenon less prominent with GHRP-6. Hexarelin's tachyphylactic properties complicate long-duration research protocols, limiting its utility compared to GHRP-6 in extended studies.
GHRP-6 vs. Ipamorelin
The most consequential comparison in GHRP research is between GHRP-6 and ipamorelin. As established by Raun and colleagues in the landmark 1998 ipamorelin characterization study (PubMed), ipamorelin is the first GHS-R1a agonist to achieve selectivity for GH release comparable to GHRH itself — stimulating robust GH output while leaving cortisol, ACTH, prolactin, and appetite essentially unchanged at any studied dose.
The key distinctions:
| Parameter | GHRP-6 | Ipamorelin |
|---|---|---|
| GH release potency | Strong (ED₅₀ ~3.9 nmol/kg) | Moderate-Strong (ED₅₀ ~2.3 nmol/kg) |
| Cortisol/ACTH | Significant dose-dependent increase | No significant change |
| Prolactin | Moderate increase | Minimal change |
| Appetite stimulation | Pronounced (ghrelin-like) | Minimal |
| Desensitization risk | Moderate | Low |
| Cytoprotective activity (CD36) | Yes (established) | Less characterized |
| Historical significance | First synthetic GHRP | First selective GHRP |
For research protocols where isolating the GH/IGF-1 axis is the experimental goal — studying body composition, bone density, sleep architecture, or metabolic outcomes — ipamorelin's selectivity provides a cleaner signal. GHRP-6 remains preferred when its distinctive properties are the subject of investigation: its full ghrelin-mimetic pharmacology, its appetite stimulation, or its broader cytoprotective actions via CD36.
GHRP-6 vs. MK-677 (Ibutamoren)
MK-677 is an orally bioavailable, non-peptide GHS-R1a agonist with a much longer half-life (>24 hours) than GHRP-6. Unlike GHRP-6, MK-677 produces sustained rather than pulsatile GH elevation, significant cortisol-sparing (minimal HPA axis activation), but notable appetite stimulation and water retention. The oral route and sustained action make MK-677 more convenient for chronic protocols, but its non-pulsatile GH profile and distinct pharmacokinetics make GHRP-6 preferable for studies specifically examining pulsatile GH secretion dynamics or short-window GH axis provocation testing.
GHRP-6 vs. Sermorelin / CJC-1295
Sermorelin and CJC-1295 are GHRH analogs — they work through the GHRH receptor rather than GHS-R1a. Combining GHRP-6 with these GHRH analogs produces synergistic GH release that substantially exceeds either compound alone. This is the primary rationale for GHRP-6 + GHRH analog combination protocols in research — see the Growth Hormone Secretagogues Compared article for full comparative analysis.
---
Research Protocols and Dosing
Standard Research Doses
Research protocols for GHRP-6 have typically employed the following dose ranges:
GH stimulation testing: 1–2 mcg/kg intravenous or subcutaneous bolus; this range produces reliable, measurable GH responses for provocation testing purposes.
Repeated-dose research protocols: 100 mcg subcutaneous injections 2–3 times daily, administered in a fasted state (2+ hours post-meal, ≥30 minutes pre-meal). At this dose, the GH response is at or near saturation, providing consistent GH pulses without disproportionate cortisol co-secretion.
Cytoprotective and tissue-repair research: Doses in preclinical studies range widely depending on the model; cardioprotection and anti-fibrotic studies have used intravenous and systemic dosing at research-equivalent levels.
Key Protocol Considerations
Fasted state requirement: GHRP-6, like all GHRPs, produces substantially reduced GH responses in the fed state due to elevated glucose and insulin enhancing somatostatin tone. Fasted administration (typically 2+ hours after last meal) is essential for reliable GH stimulation.
Timing relative to circadian GH rhythms: The largest natural GH pulse in adult humans occurs during early slow-wave sleep. Research protocols timed to align with this natural pulse (late-night administration) maximize the synergy between GHRP-6's pharmacological signal and the endogenous circadian GH drive.
Combination with GHRH analogs: Adding a GHRH analog such as Sermorelin or CJC-1295 DAC to GHRP-6 is consistently shown to amplify GH release several-fold. The CJC-1295 vs. Ipamorelin Comparison article discusses the relative merits of different GHRH + GHRP combinations.
Peptide calculator: Use the peptide dosing calculator to determine reconstitution volumes and injection volumes for different vial sizes and target doses.
Desensitization Considerations
Unlike hexarelin, GHRP-6 shows relatively modest tachyphylaxis with chronic use, particularly when administered intermittently (2–3 times daily) rather than continuously. Studies in rats and humans suggest that standard multiple-daily-injection protocols maintain adequate GH-stimulating response for months without significant receptor downregulation. However, very high doses or continuous infusion accelerates GHS-R1a internalization, motivating the use of pulsed rather than continuous administration in research protocols.
---
Research Specifications
| Parameter | Value |
|---|---|
| Molecular formula | C₄₆H₅₆N₁₂O₆ |
| Molecular weight | 873.01 Da |
| CAS Number | 87616-84-0 |
| Sequence | His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂ |
| Primary receptor | GHS-R1a (ghrelin receptor) |
| Secondary receptor | CD36 |
| Half-life | ~15–60 minutes |
| Route of administration | Subcutaneous (research); IV (clinical) |
| Reconstitution | Bacteriostatic water |
| Storage (lyophilized) | -20°C; stable 24+ months |
| Storage (reconstituted) | 2–8°C for up to 4 weeks |
| Classification | For laboratory research use only (RUO) |
---
Safety Profile in Research Contexts
Clinical Trial Safety Data
GHRP-6 has been administered in numerous human studies over several decades without major safety signals at research doses. The most consistently reported effects in clinical studies include:
Transient cortisol/ACTH elevation: Dose-dependent, typically resolving within 2–4 hours. At standard research doses (100 mcg subcutaneous), cortisol elevation is modest and generally considered manageable within protocol design.
Appetite increase: The most prominent and consistent subjective effect in human volunteers. In controlled settings, this manifests as increased hunger ratings and ad libitum food intake. Protocol-level dietary control is standard practice.
Water retention: Some subjects report mild transient water retention with repeated GHRP-6 administration, attributable to GH-mediated aldosterone effects.
Injection site reactions: Occasional mild redness or discomfort at subcutaneous injection sites; resolves spontaneously.
Dizziness/flushing: Occasional brief reports of lightheadedness or warmth shortly after injection, likely related to the acute GH spike's cardiovascular effects.
In the 2024 Phase I/II stroke trial, intravenous GHRP-6 at doses of 3.5–5 mg twice daily for 7 days was found to be safe in patients with acute ischemic stroke — a vulnerable population — providing strong safety data at doses substantially higher than typical preclinical research protocols.
Regulatory Classification
GHRP-6 is classified as a research use only (RUO) compound. It is not approved by the FDA or EMA for any therapeutic indication. In many jurisdictions it is not controlled under pharmaceutical regulations but is subject to research use restrictions. Regulatory status varies by country; researchers must confirm applicable local regulations before use.
GHRP-6 is included on the World Anti-Doping Agency (WADA) prohibited list as a growth hormone secretagogue, banning its use in competitive sport.
---
Historical Significance and Research Legacy
GHRP-6 occupies a unique position in the history of peptide endocrinology and drug development. Its discovery by Bowers in the early 1980s established that:
1. A second GH-stimulatory pathway exists distinct from and parallel to the GHRH receptor, fundamentally altering the scientific understanding of GH regulation
2. Synthetic peptides could mimic endogenous GH-releasing activity through a non-GHRH mechanism, opening an entirely new pharmacological approach to GH secretagogue drug development
3. Ghrelin's eventual identification was only possible because GHRP-6 had established the existence and pharmacological properties of the GHS-R1a receptor system years earlier
The GHRP-6 → GHS-R1a → ghrelin discovery chain represents one of the most elegant examples of pharmacological "orphan receptor" research leading to the identification of a major endogenous hormone system. Ghrelin is now recognized as a central regulator of energy homeostasis with widespread physiological functions, and its discovery would likely have been significantly delayed without the receptor characterization work that GHRP-6 enabled.
GHRP-6's expanding cytoprotective research profile — from the 78% reduction of myocardial infarct mass in porcine models to the 90%+ keloid prevention in rabbit wound models to the first Phase I/II clinical trial in acute ischemic stroke — suggests that this peptide's research legacy continues to expand well beyond its original GH-stimulatory application.
---
Comparison with Other GH Secretagogues: Full Summary Table
| Compound | Receptor | GH Release | Cortisol/ACTH | Prolactin | Appetite | Cytoprotection | Administration |
|---|---|---|---|---|---|---|---|
| GHRP-6 | GHS-R1a + CD36 | Strong | Moderate-High increase | Moderate increase | Pronounced | Yes (CD36) | SC/IV |
| GHRP-2 | GHS-R1a | Very Strong | High increase | Significant increase | Moderate | Less studied | SC/IV |
| Hexarelin | GHS-R1a | Very Strong | High increase | High increase | Moderate | Yes | SC/IV |
| Ipamorelin | GHS-R1a | Strong | No significant change | Minimal change | Minimal | Less studied | SC |
| MK-677 | GHS-R1a | Strong (sustained) | Minimal | Minimal | Moderate | Less studied | Oral |
| Sermorelin | GHRH-R | Moderate | No significant change | None | None | Limited | SC |
| CJC-1295 DAC | GHRH-R | Moderate (sustained) | No significant change | None | None | Limited | SC |
See the full Growth Hormone Secretagogues Compared analysis for detailed receptor pharmacology, clinical evidence, and research application guidance.
---
> Research Disclaimer: GHRP-6 is a synthetic peptide intended for laboratory and preclinical research use only. It is not approved for human therapeutic use by the FDA, EMA, or any other regulatory authority. The information in this article is provided for educational and scientific research purposes only and does not constitute medical advice. GHRP-6 is included on the WADA prohibited list and is not approved for use in competitive athletics. All research use must comply with applicable local regulations and institutional review requirements.
---
Further Reading:
- •Ghrelin: The Acylated Gastric Peptide Driving Growth Hormone, Energy Homeostasis, and Neuroprotection Research
- •GHRP-2 (Pralmorelin): The Potent Second-Generation Growth Hormone Secretagogue — Complete Research Profile
- •Ipamorelin: The Selective Growth Hormone Secretagogue — Complete Research Profile
- •MK-677 (Ibutamoren): Complete Research Profile — Oral GH Secretagogue, Mechanism, Clinical Data
- •Reconstitution Calculator
- •Peptide Stack Builder